AGER and diabetes mellitus: Moreover, azeliragon (PF-04494700 or TTP488), an oral antagonist of RAGE, has obtained favorable results in animal models of Alzheimer’s disease and was proven safe and effective at low doses in diverse clinical trials [191,192] (NCT02080364), being established as a promising therapeutic agent in the management of chronic complications of DM such as diabetic retinopathy [193].